000181957 001__ 181957
000181957 005__ 20240229145703.0
000181957 0247_ $$2doi$$a10.1186/s12885-022-10109-1
000181957 0247_ $$2pmid$$apmid:36195836
000181957 0247_ $$2altmetric$$aaltmetric:136800721
000181957 037__ $$aDKFZ-2022-02327
000181957 041__ $$aEnglish
000181957 082__ $$a610
000181957 1001_ $$aLeichsenring, Jonas$$b0
000181957 245__ $$aEVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
000181957 260__ $$aHeidelberg$$bSpringer$$c2022
000181957 3367_ $$2DRIVER$$aarticle
000181957 3367_ $$2DataCite$$aOutput Types/Journal article
000181957 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1665038848_20168
000181957 3367_ $$2BibTeX$$aARTICLE
000181957 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181957 3367_ $$00$$2EndNote$$aJournal Article
000181957 500__ $$a#LA:A380#
000181957 520__ $$aOverexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we aimed to investigate frequency and clinical relevance of EVI1 expression in newly diagnosed BC treated with neoadjuvant chemotherapy.EVI1 expression was determined by immunohistochemistry using H-score as a cumulative measurement of protein expression in pretherapeutic biopsies of BC patients treated with anthracycline/taxane based neoadjuvant chemotherapy within the GeparTrio trial. EVI1 was analyzed as a continuous variable and dichotomized into low or high based on median expression. Endpoints were pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS).Of the 993 tumors analyzed, 882 had available subtype information: 50.8% were HR + /HER2-, 15% HR + /HER2 + , 9.8% HR-/HER2 + , and 24.5% TNBC. Median EVI1 H-score was 112.16 (range 0.5-291.4). High EVI1 expression was significantly associated with smaller tumor size (p = 0.002) but not with BC subtype. Elevated EVI1 levels were not significantly associated with therapy response and survival in the entire cohort or within BC subtypes. However, TNBC patients with high EVI1 showed a trend towards increased pCR rates compared to low group (37.7% vs 27.5%, p = 0.114; odds ratio 1.60 (95%CI 0.90-2.85, p = 0.110) and numerically better DFS (HR = 0.77 [95%CI 0.48-1.23], log-rank p = 0.271) and OS (HR = 0.76 [95% 0.44-1.31], log-rank p = 0.314) without reaching statistical significance.EVI1 was not associated with response to neoadjuvant therapy or patient survival in the overall cohort. Further analyses are needed to verify our findings especially in the pathological work-up of early-stage HER2-negative BC patients.NCT00544765.
000181957 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000181957 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181957 650_7 $$2Other$$aBreast cancer
000181957 650_7 $$2Other$$aEVI1
000181957 650_7 $$2Other$$aNeoadjuvant chemotherapy
000181957 7001_ $$aVladimirova, Valentina$$b1
000181957 7001_ $$aSolbach, Christine$$b2
000181957 7001_ $$aKarn, Thomas$$b3
000181957 7001_ $$aAtaseven, Beyhan$$b4
000181957 7001_ $$aSinn, Bruno Valentin$$b5
000181957 7001_ $$aBarinoff, Jana$$b6
000181957 7001_ $$aMüller, Volkmar$$b7
000181957 7001_ $$aBlohmer, Jens-Uwe$$b8
000181957 7001_ $$aSchem, Christian$$b9
000181957 7001_ $$aEngels, Knut$$b10
000181957 7001_ $$aMarmé, Frederik$$b11
000181957 7001_ $$aFisseler-Eckhoff, Annette$$b12
000181957 7001_ $$aFasching, Peter A$$b13
000181957 7001_ $$aStickeler, Elmar$$b14
000181957 7001_ $$avan Mackelenbergh, Marion$$b15
000181957 7001_ $$aDenkert, Carsten$$b16
000181957 7001_ $$aStenzinger, Albrecht$$b17
000181957 7001_ $$aLoibl, Sibylle$$b18
000181957 7001_ $$0P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aGröschel, Stefan$$b19$$eLast author
000181957 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-022-10109-1$$gVol. 22, no. 1, p. 1040$$n1$$p1040$$tBMC cancer$$v22$$x1471-2407$$y2022
000181957 909CO $$ooai:inrepo02.dkfz.de:181957$$pVDB
000181957 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000181957 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000181957 9141_ $$y2022
000181957 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000181957 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000181957 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000181957 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000181957 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000181957 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:36Z
000181957 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:36Z
000181957 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-02-14T16:18:36Z
000181957 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000181957 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000181957 9202_ $$0I:(DE-He78)A380-20160331$$kA380$$lNWG Molekulare Leukämogenese$$x0
000181957 9201_ $$0I:(DE-He78)A380-20160331$$kA380$$lNWG Molekulare Leukämogenese$$x0
000181957 980__ $$ajournal
000181957 980__ $$aVDB
000181957 980__ $$aI:(DE-He78)A380-20160331
000181957 980__ $$aUNRESTRICTED